Caricamento...
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
We have shown that WT-161, a histone deacetylase 6 (HDAC6) inhibitor, shows remarkable anti-tumor activity in multiple myeloma (MM) in preclinical models. However, its activity in other type of cancers has not yet been shown. In this study, we further evaluated the biologic sequelae of WT161 in brea...
Salvato in:
| Pubblicato in: | Oncotarget |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Impact Journals LLC
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5655183/ https://ncbi.nlm.nih.gov/pubmed/29113288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19019 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|